跳至主要内容
临床试验/EUCTR2016-003991-27-NL
EUCTR2016-003991-27-NL进行中(未招募)1 期

MAAST: A Double-blind, Randomized, Phase IV, Mechanistic, Placebo-controlled, Cross-over, Single-center Study to Evaluate the Effects of 5 Weeks Dapagliflozin Treatment on Insulin Sensitivity in Skeletal Muscle in Type 2 Diabetes Mellitus Patients - DAPAMAAST

AstraZeneca AB0 个研究点目标入组 26 人开始时间: 2017年10月25日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
26

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Provision of signed and dated, written informed consent prior to any study specific procedures
  • Post-menopausal females aged between = 45 and = 70 years and/or males aged between = 40 years and = 70 years. Patients should have suitable veins for cannulation or repeated venipuncture.
  • Patients diagnosed with T2DM for at least the last 6 months, based on American Diabetes Association 2016 standards.
  • Patients on no other anti-diabetic drug treatment, or on stable maximum 3000 mg daily dose metformin treatment and/or on stable dose of a DPPIV inhibitor treatment for at least the last 3 months
  • HbA1c levels =6.0% (=42 mmol/mol) and =9.0% (75 mmol/mol)
  • Body mass index (BMI) = 38 kg/m2
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 18
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 8

排除标准

  • Any of clinically significant disease or disorder including a recent cardiovascular event
  • Diagnosis of Type 1 Diabetes Mellitus, maturity onset diabetes of the young, secondary diabetes or diabetes insipidus
  • Unstable/rapidly progressing renal disease or estimated Glomerular Filtration Rate < 60 mL/min (Cockcroft-Gault formula)
  • History of drug abuse or alcohol abuse in the past 12 months
  • Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis
  • Contraindications to dapagliflozin according to the local label
  • Anemia defined as Hemoglobin (Hb) < 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men.
  • Use of anti-coagulant treatment
  • Use of medication such as oral glucocorticoids, anti-estrogens or other medications that are known to markedly influence insulin sensitivity
  • Use of loop diuretics
  • Regular smoking /nicotine use
  • Any contra-indication to magnetic resonance imaging scanning
  • Patients, who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study.

研究者

相似试验